阿斯利康第三季度利润涨幅超出预期，主要得益于其蓬勃发展的肿瘤学业务。
Plc profit rose more than expected in the third quarter, driven by its booming oncology business.
剔除某些项目后的每股收益为2.79美元，高于彭博社调查的分析师预估的2.62美元。重磅抗癌药物英飞凡和泰瑞沙的销售额均超出预期。这家英国药企还重申了全年业绩指引。
Earnings per share, excluding some items, were $2.79, higher than the $2.62 estimated by analysts surveyed by Bloomberg. Sales for blockbuster cancer drugs like Imfinzi and Tagrisso were higher than expected. The British drugmaker also reconfirmed its guidance for the year.
尽管销售额持续增长，但投资者对阿斯利康保持谨慎态度，因为该公司今年在临床试验中遭遇了几次挫折，这对于一向习惯持续传出利好消息的公司来说属于罕见情况。自今年初以来，该公司股价已下跌5.4%。
Even as sales continue to rise, investors have been cautious on AstraZeneca after several setbacks in its clinical trials this year, an unusual occurrence for the company more used to a steady stream of positive results. Shares have fallen by 5.4% since the start of the year.